针对 SARS-CoV-2 的中和抗体反应：基于人群的血清流行病学分析。
Neutralizing antibody responses to SARS-CoV-2: A population based seroepidemiological analysis.
机构信息
Department of Community Medicine, Maulana Azad Medical College, New Delhi, India.
Department of Clinical Virology, Institute of Liver and Biliary Sciences, New Delhi, India.
出版信息
Indian J Med Microbiol. 2022 Oct-Dec;40(4):585-587. doi: 10.1016/j.ijmmb.2022.07.009. Epub 2022 Aug 8.
This study (August-September 2021) estimated the seroprevalence of SARS-CoV-2 neutralizing antibodies in the general population of Delhi and correlated it with their anti-SARS-CoV-2 IgG levels. Samples were selected by simple random sampling method. The neutralizing capacity was estimated by performing a surrogate virus neutralization test (sVNT) (GenScript), Piscataway, NJ, USA. A total of 2233 (87.1%, 95% C.I. 85.7, 88.3) of the 2564 SARS-CoV-2 IgG seropositive samples had detectable SARS-CoV-2 neutralizing antibodies. In samples with S/CO ≥ 4.00, the neutralizing antibodies ranged from 94.5% to 100%. The SARS-CoV-2 neutralizing antibody seroprevalence strongly correlated with the S/CO range of IgG SARS-CoV-2 (r = 0.62, p = 0.002).
本研究（2021 年 8-9 月）估计了德里普通人群中 SARS-CoV-2 中和抗体的血清流行率，并将其与抗 SARS-CoV-2 IgG 水平相关联。样本采用简单随机抽样法选取。中和能力通过进行替代病毒中和试验（sVNT）（美国新泽西州皮斯卡塔韦的 GenScript）进行评估。在 2564 份 SARS-CoV-2 IgG 血清阳性样本中，共有 2233 份（87.1%，95%置信区间 85.7%，88.3%）可检测到 SARS-CoV-2 中和抗体。在 S/CO 值≥4.00 的样本中，中和抗体的范围为 94.5%至 100%。SARS-CoV-2 中和抗体血清流行率与 IgG SARS-CoV-2 的 S/CO 范围呈强相关性（r=0.62，p=0.002）。
Zotero 插件